Regeneron Pharmaceuticals (NASDAQ:REGN) Earns “Sector Perform” Rating from Royal Bank Of Canada

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “sector perform” rating reaffirmed by equities researchers at Royal Bank Of Canada in a note issued to investors on Tuesday, Benzinga reports. They currently have a $737.00 target price on the biopharmaceutical company’s stock. Royal Bank Of Canada’s price target would indicate a potential downside of 0.97% from the company’s previous close.

A number of other equities analysts also recently weighed in on REGN. Citigroup boosted their target price on shares of Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd. Sanford C. Bernstein raised shares of Regeneron Pharmaceuticals to a “hold” rating in a research note on Wednesday, July 29th. Cantor Fitzgerald boosted their price objective on shares of Regeneron Pharmaceuticals from $750.00 to $795.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Benchmark upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price objective for the company in a report on Tuesday, July 7th. Finally, Piper Sandler reduced their price target on shares of Regeneron Pharmaceuticals from $855.00 to $854.00 and set an “overweight” rating for the company in a report on Thursday, July 9th. Fourteen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $802.18.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded down $8.04 during midday trading on Tuesday, hitting $744.21. The company had a trading volume of 80,906 shares, compared to its average volume of 826,360. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The stock has a market cap of $76.62 billion, a price-to-earnings ratio of 18.40, a P/E/G ratio of 1.54 and a beta of 0.20. The firm has a fifty day simple moving average of $781.41 and a two-hundred day simple moving average of $720.99. Regeneron Pharmaceuticals has a fifty-two week low of $541.00 and a fifty-two week high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts’ consensus estimates of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm’s revenue for the quarter was up 16.7% compared to the same quarter last year. During the same period last year, the firm earned $12.81 EPS. Equities analysts forecast that Regeneron Pharmaceuticals will post 44.25 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Arthur Ryan sold 200 shares of the stock in a transaction dated Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the transaction, the director directly owned 17,303 shares of the company’s stock, valued at $11,249,545.45. This represents a 1.14% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $850.00, for a total transaction of $340,000.00. Following the completion of the transaction, the director directly owned 603 shares in the company, valued at $512,550. The trade was a 39.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 4,146 shares of company stock valued at $3,432,488. 6.97% of the stock is owned by insiders.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Western Wealth Management LLC bought a new position in Regeneron Pharmaceuticals in the 1st quarter valued at about $26,000. SHP Wealth Management acquired a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $26,000. Titan Wealth CI Ltd acquired a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth approximately $29,000. MCF Advisors LLC lifted its position in shares of Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 45 shares of the biopharmaceutical company’s stock worth $35,000 after purchasing an additional 15 shares during the period. Finally, Mowery & Schoenfeld Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $29,000. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron’s Libtayo cancer treatment is being evaluated in combination with Biohaven’s experimental BHV-1530 in patients with solid tumors, with enrollment in the combination cohort already underway. The agreement could support additional clinical applications and potential long-term growth for Libtayo. Why Did Regeneron Pharmaceuticals Stock Drop Today?
• Neutral Sentiment: Regeneron is expected to report third-quarter results next month, making the upcoming earnings release a potential catalyst. Investors will likely focus on Eylea sales, operating performance and updates on the company’s broader pipeline. Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30?
• Negative Sentiment: Kodiak Sciences reported Phase 3 data indicating that its investigational eye drugs, Zenkuda and tabirafusp alfa tedromer, matched Eylea on key efficacy endpoints for wet age-related macular degeneration. Their roughly six-month dosing interval, compared with Eylea’s typical eight-week schedule, raises concerns about future competitive pressure and potential pricing or market-share erosion. Kodiak skyrockets on positive study data for two eye drugs
• Negative Sentiment: Royal Bank of Canada reaffirmed its “sector perform” rating and set a $737 price target, below the reference price, signaling limited near-term upside in the analyst’s view. Royal Bank of Canada rating update

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron’s marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.